Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Alan K, Matsumoto"'
Autor:
Alan K. Matsumoto, Herbert S B Baraf
Publikováno v:
International Journal of Clinical Rheumatology. 7:143-154
Although pharmacologic therapies for hyperuricemia in patients with gout have been well established and are reasonably effective, a small proportion of patients are refractory to treatment and/or present with articular disease so severe as to render
Publikováno v:
Pain Medicine. 6:357-366
Objective. To compare oxymorphone extended release (ER) and placebo on indices of pain, function, and safety in patients with chronic osteoarthritis (OA) pain. Design. In this multicenter, double-blind, placebo- and active-controlled, parallel-group,
Autor:
Arthur L. Weaver, Gregory P. Geba, Nathaniel P. Katz, Wendy P. Battisti, Adam B. Polis, Alan J. Kivitz, Alan K. Matsumoto
Publikováno v:
The Journal of Pain. 5:511-520
We compared onset of efficacy (during days 1 to 6) of 2 coxibs (rofecoxib, celecoxib) with acetaminophen and nabumetone by using a prespecified approach to data from 4 similarly designed 6-week randomized osteoarthritis trials. In 2 trials, rofecoxib
Autor:
Jerry Green, Richard A. Petruschke, Robert A. Moidel, Alan K. Matsumoto, Daryl K. Najarian, Alan Kivitz, Mary E. Dixon, Stanley Cohen, Adam B. Polis, Gregory P. Geba, Herbert S. B. Baraf, Maria Greenwald
Publikováno v:
Journal of the American Geriatrics Society. 52:666-674
To evaluate the use of starting doses of rofecoxib and nabumetone in patients with osteoarthritis (OA) of the knee.A 6-week, randomized, parallel-group, double-blind, placebo-controlled study.One hundred thirteen outpatient sites in the United States
Publikováno v:
Arthritis & Rheumatism. 49:778-783
Objective. To evaluate spirituality, well-being, and quality of life (QOL) among people with rheumatoid arthritis (RA). Methods. Questionnaires assessing positive and negative affect, depression, QOL and spirituality were completed. Disease activity
Autor:
Steven P. Richieri, Joseph A. Markenson, Eric L. Matteson, Joseph M. Cash, Larry W. Moreland, Cornelia M. Weyand, William J. Koopman, Christopher J. Nardo, Leonard H. Calabrese, Joan M. Bathon, Elizabeth E Morgan, Dennis J. Carlo, Steven W. Brostoff, K. M. Uramoto, Thomas C. Adamson, Alan K. Matsumoto, Jocelyn P. Diveley, Zdenka Fronek, Louis W. Heck, Vibeke Strand
Publikováno v:
Arthritis & Rheumatism. 41:1919-1929
OBJECTIVE Restricted T cell receptor (TCR) gene usage has been demonstrated in animal models of autoimmune disease and has resulted in the successful use of TCR peptide therapy in animal studies. This clinical trial was undertaken to determine the sa
Autor:
Robert H. Carter, Joseph M. Ahearn, Doughs T. Fearon, Don R. Martin, Lloyd B. Klickstein, Alan K. Matsumoto
Publikováno v:
The Journal of Experimental Medicine
The CD21/CD19/TAPA-1 complex of B lymphocytes amplifies signal transduction through membrane immunoglobulin (mIg), recruits phosphatidylinositol 3-kinase (PI3-kinase), and induces homotypic cellular aggregation. The complex is unique among known memb
Autor:
Alan K Matsumoto
Publikováno v:
Expert opinion on pharmacotherapy. 8(10)
Opana ER (oxymorphone extended release [ER]) is a new oral long-acting formulation indicated for the treatment of moderate to severe chronic pain. Because the ER matrix slowly releases oxymorphone over 12 h, consistent plasma levels are produced with
Autor:
Alan K, Matsumoto, Paul F, Cavanaugh
Publikováno v:
Drugs of today (Barcelona, Spain : 1998). 40(5)
Etoricoxib (Arcoxia, MerckCo., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation. It is a member of the COX-2-selective (coxib) class of nonsteroidal antiinflammatory drugs (NSAIDs). Extensive cli
Autor:
Alan J, Kivitz, Maria W, Greenwald, Stanley B, Cohen, Adam B, Polis, Daryl K, Najarian, Mary E, Dixon, Robert A, Moidel, Jerry A, Green, Herbert S B, Baraf, Richard A, Petruschke, Alan K, Matsumoto, Gregory P, Geba
Publikováno v:
Journal of the American Geriatrics Society. 52(5)
To evaluate the use of starting doses of rofecoxib and nabumetone in patients with osteoarthritis (OA) of the knee.A 6-week, randomized, parallel-group, double-blind, placebo-controlled study.One hundred thirteen outpatient sites in the United States